Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ArtemiCoffee
- Development stage
- Phase 2
- Lead developer
- ArtemiLife
- Administration
- Oral
01
Overview
ArtemiCoffee is a decaffeinated coffee product containing a controlled dose of Artemisia annua (sweet annie or sweet wormwood), a plant traditionally used for medicinal purposes. The product is designed to deliver artemisinin, the active compound in Artemisia annua that has shown potential anti-cancer properties. ArtemiCoffee's patent-pending formulation uses properties of coffee to stabilize the active ingredient longer and increase effectiveness. The product is being developed and tested as a maintenance therapy for cancer patients, particularly those with prostate and ovarian cancers.
- Brand names
- ArtemiCafe
- Other names
- Artemisia annua coffeeAa coffeeAa decaf coffee
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on ArtemiCoffee.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArtemiCoffee.